Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients

Ocrelizumab is often used as an alternative therapy in natalizumab-treated MS patients at risk for progressive multifocal leukoencephalopathy (PML). Our objective was to assess efficacy and safety of JC-virus positive patients switching (either directly or indirectly) from natalizumab to ocrelizumab...

Descripción completa

Detalles Bibliográficos
Autores principales: van Lierop, ZYGJ, Toorop, AA, Coerver, EME, Willemse, EAJ, Strijbis, EMM, Kalkers, NF, Moraal, B, Barkhof, F, Teunissen, CE, Killestein, J, van Kempen, ZLE
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175839/
https://www.ncbi.nlm.nih.gov/pubmed/34123391
http://dx.doi.org/10.1177/20552173211013831

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175839/
https://www.ncbi.nlm.nih.gov/pubmed/34123391
http://dx.doi.org/10.1177/20552173211013831

Ejemplares similares